



2019 台灣胸腔暨重症加護醫學會

2019 Taiwan Society of Pulmonary and Critical Care Medicine

The role of M2a monocyte polarization and formyl peptide receptor (FPR)1/2/3 expressions in the progression from latent TB infection to active pulmonary TB disease

血液第2a型單核球極化和第一、二、三型甲酰肽受器在潛伏性結核感染進展至活動性肺結核疾病所扮演的角色

陳永哲 醫師 高雄長庚醫院 胸腔內科



時間：2019/12/07 PM 16:40 ~ 16:50

地點：高雄展覽館3樓 304A




In their naive stage, **alveolar macrophages** (AMs) that phagocytose the inhaled *M.tb* at alveoli exhibit an **M2-like** phenotype that is more permissive for the growth of *M. tuberculosis*.

Front. Microbiol 2018. 9:1028.




With **IFN- γ** -mediated priming through T cells, AMs could exhibit the **M1**-like phenotype at the early stage of infection and **restrict** bacterial growth. AMs eventually acquire an **M2**-like phenotype after **inflammation** progresses.

J Leukoc Biol. 2019;106:275–282.



During the **advanced** disease stage TB, the macrophages adapt to an **M2**- polarization state, whereby metabolic reprogramming leads to the expression of **anti-inflammatory** cytokines such as IL-4, IL-10, and TGF- β , and increased **phagocytosis**.


Front Mol Biosci. 2019 Oct 14;6:105.



Phagocytosis is a specific form of endocytosis by which cells internalise solid matter (microbial pathogens).


Efferocytosis involves the regulated uptake & degradation of apoptotic bodies.

Curr Opin Microbiol. 2014 February ; 0: 17–23




As a marker of **efferocytosis**, **Formyl Peptide Receptors (FPRs) 1/2/3** play a distinct role in myeloid cell **adhesion/activation**, and macrophage **phagocytosis**.

Pharmacology & Therapeutics 127 (2010) 175–188



FPR1 maintains **chemotaxis** and **superoxide** production of resting and pro-inflammatory **M1** macrophages, while **FPR2** skews monocyte into **M2a/c/b/d**.

- **M1** Polarization of macrophages with IFN- γ , LPS and with the TLR8 ligand 3M-2
 - further **increases FPR1** mRNA levels
 - not consistently increase protein expression or chemotaxis towards the FPR1 ligand fMLF.
- **M2** polarization of primary human macrophages with IL-4 and IL-13 leading to the alternative activated macrophages
 - **reduces FPR1** cell surface expression and abolishes chemotaxis towards fMLF





- FPR2 stimulation (AnxA1)
- decreased **neutrophil-endothelial** interactions by 25-45%
- stimulated neutrophil apoptosis and **macrophage efferocytosis** by 45%.

FPR1/FPR2 on neutrophils mediate a rapid **neutrophil influx** in response to **Listeria** infection, while **FPR3** in neutrophils is enhanced by **LPS** stimuli.

Both Fpr1 and Fpr2 expressed by mouse neutrophils sense bacteria-derived chemotactic PAMPs to mediate a rapid neutrophil influx into the liver of listeria-infected mice.

Fpr3 (a decoy receptor) Expression in Neutrophils Is Enhanced by LPS Stimulation in mice



THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 291, pp. 9762–9775, 2016

Little is known about the role of FPR1/2/3 in human immune responses against *M.tb*.

Mycobacteria can activate **FPR1** on **monocyte** and **PMN**.

- Mycobacteria contain **formyl peptides**, which are released during bacterial lysis.
- **Increased FPR1** gene expression of blood **monocytes** in **active TB** patients vs. **LTBI** subjects.
- Antagonize the anti-inflammatory effects induced by formyl peptides in monocytes/PMN from TB patients.
- Mycobacteria **butyricum** **activate FPR1 on neutrophils**, resulting in tonic secretion of opioid peptides from neutrophils and in a decrease in inflammatory pain.


Clin Exp Immunol. 2003 Aug;133(2):267-74.

J Mol Med (Berl). 2007 Jun;85(6):613-21.

PLoS Pathog. 2009 Apr;5(4):e1000362.





Hypothesis of the current study

- Monocyte M1/M2 polarization and the FPR1/2/3 expressions of peripheral blood immune cells may be different between
 - active pulmonary TB patients, latent TB infection (LTBI) patients, and non-infected healthy subjects (NIHS)
 - between TB patients with and without specific clinical phenotypes, such as high bacterial load, advanced lesions on chest radiograph, and systemic symptoms



Study subjects and Method



- Blood CD14⁺CD209⁻**M1** / CD14⁺CD209⁺**M2a** monocyte percentage by **flowcytometry**
- **FPR1/FPR2/FPR3** protein expressions of blood M1 monocyte, M2 monocyte, neutrophil, natural killer (NK) cells, T helper (Th) cell, and cytotoxic T (Tc) cell measured by **flowcytometry**.
- Participants
 - **43** patients with **sputum culture (+)** active pulmonary TB disease
 - **11** subjects with LTBI (**IGRA+**, **contact Hx+**)
 - **23** non-infected healthy subjects (NIHS; **IGRA-**, **contact Hx+**)





Demographic, co-morbidity, and clinical data of all the 70 study participants

	Non-infected healthy subjects N = 23	Subjects with latent TB infection N = 11	Patients with active pulmonary TB disease N = 43	P value
Age, years	51.4±17.2	53.2±14	56.3±13.6	0.512
Male sex, n (%)	10 (43.3)	6 (61.1)	43 (57.5)	0.542
Co-morbidity, n (%)				
Hypertension	7 (26.9)	3 (27.3)	13 (28.9)	0.982
Diabetes mellitus	4 (15.4)	2 (18.2)	13 (28.9)	0.393
COPD/Asthma	2 (7.7)	0 (0)	6 (13.3)	0.374
Chronic hepatitis	3 (11.5)	2 (18.2)	4 (8.9)	0.672
Chronic kidney disease	0 (0)	1 (5.6)	0 (0)	0.231
Heart failure	0 (0)	0 (0)	1 (2.2)	0.66
Alcoholism, n (%)	0 (0)	0 (0)	3 (6.7)	0.468
Current Smoking, n (%)	3 (15.8)	1 (10)	9 (30)	0.304
IGRA (+), n (%)	0 (0)	11 (100)	NA	
Acid fast bacilli 1-4, n (%)			25 (55)	
Drug-resistant TB, n (%)			10 (25)	
Systemic symptoms, n (%)			15 (34.8)	

CD14⁺CD209⁻ **M1** monocyte percentage was significantly **decreased** in **active TB** group as compared with either NIHS or LTBI group, and **negatively** correlated with **FPR3** expression of M1 monocyte.




CD14⁺CD209⁺ **M2a** monocyte percentage was **increased** in **active TB** group versus either NIHS or LTBI group, and **positively** correlated with **FPR3** expression of M2a monocyte.




Diagnostic accuracy of the **reverse of M1** monocyte percentage and **M2a/M1 percentage ratio** measured at diagnosis for discrimination between active TB disease and LTBI+NIHS

Reverse of M1%



AUC: 0.717, 95%CI 0.597-0.828, **P=0.001**
0.0139: Sensitivity 82.1%, Specificity 58.8%


M2a/M1 % ratio




AUC: 0.698, 95%CI 0.582-0.814, **p=0.003**
0.721: sensitivity 62.8%, specificity 61.8%

FPR3 protein expression of CD16⁺ **neutrophil** was decreased in **active TB** group versus NIHS group, while **FPR1 over FPR2 expression ratio** on CD16⁺**neutrophil** was **increased** in **LTBI** group as compared with either NIHS or LTBI group.





FPR3 of PMN



FPR1/FPR2 expression ratio on PMN



FPR2 expressions on **M1** monocyte, **CD16+neutrophil**, and **CD3-CD56+ natural killer** cells were all **decreased** in active TB patients with **systemic symptoms** (defined as either **fever** or **body weight loss** at diagnosis; N=15) as compared with that in those without systemic symptoms (N=28) or subjects without active TB disease (NIHS+LTBI groups; N=34).



Summary and Conclusions

- A potential marker of **active TB** disease vs. NIHS or LTBI
 - Increased **M2a** monocyte percentage
 - Decreased **M1** phenotypes of blood monocyte
 - Decreased **FPR3** expression of blood **neutrophil**
 - Reverse of **M1%** showed **Good performance** of diagnosis for active TB
 - ✓ AUC 0.721, $p=0.001$, versus LTBI+NIHS
 - ✓ CUT-OFF value of 0.0139: Sensitivity 82.1%, Specificity 58.8
- A potential marker of **LTBI**
 - Increased **FPR1 over FPR2** expression ratio of blood **neutrophil**
- An association between **systemic symptoms** in active TB D's
 - Decreased **FPR2** expressions on M1 monocyte,
 - Decreased **FPR2** expression on neutrophil
 - Decreased **FPR2** expression on natural killer cells

Acknowledgement

- Professor **Meng-Chih Lin**
 - Assistant Administrator of KCGMH, Taiwan
 - Advisor
- Division of Pulmonary & Critical Care Medicine, **Kaohsiung CGMH**, Taiwan
 - Dr. Tung-Ying Chao
 - Dr. Sum-Yee Leung
 - Dr. Chao-Chien Wu
 - Dr. Wen-Feng Fang
 - Dr. Yi-Hsi Wang
- Graduate Institute of Clinical Medical Sciences, Chang Gung University College of Medicine, Taiwan
 - Professor **Chang-Chun Hsiao**
- **Internal Medicine Core Facility**, KCGMH, Taiwan
 - Ting-Ya Wang
 - Yi-Xin Zheng
 - Yong-Yong Lin
 - Chiu-Ping Lee
- Department of Medical Research
 - **Dr. Po-Yuan Hsu**



Thank You for
Your Attention